IL-17RA ANTIBODY FC FUSION PROTEIN, AND USE THEREOF

Provided are an IL-17RA antibody Fc fusion protein, a pharmaceutical composition, an injection, and a use thereof. The IL-17RA fusion protein comprises connection-operatable, sequentially and serially connected signal peptides, an IL-17RA extracellular domain, and an IgG1 constant region. The IL-17RA fusion protein of the present invention has an extended half-life, obtains longer-acting drug activity and lowered immunogenicity compared to antibody medications. The design of the present invention allows the IL-17RA fusion protein to eliminate ADCC, ADCP, and CDC effect, retains the in-vivo recycling mediated by Fc receptors (FcRn) in newborns, and has lower side reaction and is safer compared to current commercially available IL-17RA antibodies. L'invention concerne une protéine de fusion Fc d'anticorps d'IL-17RA, une composition pharmaceutique, une injection et une utilisation de celles-ci. La protéine de fusion d'IL-17RA comprend des peptides de signal connectés séquentiellement et en série, opérationnels p